* Spero Therapeutics Inc SPRO.OQ reported a quarterly
adjusted
loss of 24 cents per share for the quarter ended in March,
higher than the same quarter last year, when the company
reported EPS of -25 cents. The mean expectation of
three analysts for the quarter was for a loss of 4 cents per
share. Wall Street expected results to range from -12 cents
tozero cents per share.
* Revenue rose 347.9% to $9.27 million from a year ago;
analysts
expected $21.53 million.
* Spero Therapeutics Inc's reported EPS for the quarter was
a loss
of 24 cents.
* The company reported a quarterly loss of $12.67 million.
* Spero Therapeutics Inc shares had fallen by 7.0% this
quarter and gained 8.8% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by
about 79% in
the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for Spero
Therapeutics Inc is $7.50
This summary was machine generated from LSEG data May 15 at
09:21 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Mar. 31 2024 -0.04 -0.24 Missed
Dec. 31 2023 -0.10 0.96 Beat
Sep. 30 2023 -0.03 0.04 Beat
Jun. 30 2023 -0.34 -0.23 Beat